Frontier IP Group - Portfolio news: CRI wins EU grant
REACH - non-regulatory announcement
AIM: FIPP
Frontier IP Group plc
("Frontier IP" or the "Group")
Portfolio news - Cambridge Raman Imaging wins European grant and targets pharmaceutical control market
Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company Cambridge Raman Imaging ("CRI" or the "Company") has:
· received a
· signed a distribution agreement with Hooke Instruments Limited ("Hooke Instruments" or the "Distributor") to enter the Chinese market for medical and scientific research microscopes; and
· announced it is to target industrial quality control in the pharmaceutical sector as an initial strategic focus.
The non-dilutive EIC funding, provided by the European Union, is to be used to back the Company's move to develop its high-speed multimodal Raman imaging for use in a wide range of applications, from detecting cancerous tumours in human cells and tissue to microplastics in the environment.
Frontier IP holds a 26.81 per cent equity stake in the Company.
CRI's technology analyses multiple Raman spectra at once to create a complete chemical picture of a compound in near real time, and is much faster than other Raman systems, which analyse one spectrum at a time or chemical processes.
The Company has decided to extend its focus to develop the technology for pharmaceutical companies to use in their mass production lines to analyse the chemical composition of the tablets, pills and powders they make to ensure they contain the right amounts of active ingredients.
While CRI remains committed to the medical markets, industrial quality control provides the Company with an opportunity to scale at a faster pace because the regulatory barriers to entry are much lower.
The global market for pharmaceutical inspection equipment is currently valued at
Hooke Instruments is a specialist manufacturing and distributor of scientific and medical instruments based in
*https://www.linkedin.com/pulse/pharmaceutical-inspection-equipment-market-analysis-t6kwc/
ENQUIRIES
|
Frontier IP Group Plc |
|
|
Company website: www.frontierip.co.uk |
andrew.johnson@frontierip.co.uk M: 07415 888 425 |
|
|
|
|
Allenby Capital Limited (Nominated Adviser and Joint Broker)
|
T: 0203 328 5656 |
|
Shore Capital (Joint Broker) James Thomas /
|
T: 0207 408 4050 |
ABOUT FRONTIER IP
Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE